Skip to main content
OpenTrials
Completed

NCT Number: NCT01051583

Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma

Assess the efficacy of Avastin as an adjunct to Diode Laser cyclophotocoagulation in the treatment of Neovascular Glaucoma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neovascular Glaucoma Eye Diseases Glaucoma Glaucoma, Neovascular Ocular Hypertension

Age range

14 year–72 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Kasr El-Ainy hospital, Cairo university,ophthalmology departement

Cairo, Cairo Governorate, 11451, Egypt

About this study

Design: Prospective, comparative interventional case series. Method: Patients were randomly assigned into Group A which were treated with Diode laser cyclophotocoagulation alone, whereas group B received intravitreal Avastin (One milligram = 0.04mL of 25 mg/mL) in conjunction with the Diode Laser. The preoperative data included etiology, mean age; follow up period, and a full ophthalmological examination with emphasis on mean IOP, iris neovascularization, pain and corneal edema.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Neovascular absolute glaucoma
  • Painful blind eyes

Exclusion criteria

  • Neovascular glaucoma with useful vision or potential for useful vision

Treatment and study plan

Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin

Procedure

The operative procedure involved retro-bulbar anesthesia, draping the patient in an aseptic manner, introduction of an eye speculum, 30 laser shots over 270 degrees of the circumference of the limbus. For our study we used the Iris Diode laser machine, the G-probe and we adjusted the settings for 2500 millisecond duration and the 3000 milli-joule and reduced the power progressively until just below the energy level that produced a pop.then after applying the laser, we performed a paracentesis with a 27 gauge needle to soften the globe, followed by intravitreal injection of the Avastin from a site 3.5 millimeter posterior to the limbus. The dose we administered was one milligram of bevacizumab (0.04 mL of 25 mg/mL).

Other names: bevacizumab

Primary outcomes

  1. Disappearance of iris neovessels

    Time frame: 2 weeks

Secondary outcomes

  1. Intra ocular pressure

    Time frame: 4 weeks

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Collaborators

  • AL-Nour Eye Hospital
  • Kasr El Aini Hospital

Registry information

Official study title

Avastin as an Adjunct to Diode Laser Cyclophotoablation in the Treatment of Neovascular Glaucoma

Important dates

Study start
2006
Primary completion
2008
Study completion
2008
First posted
Jan 18, 2010
Registry last updated
Jan 18, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.